| Tumor mutational load predicts survival after immunotherapy across multiple cancer types RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ... Nature genetics 51 (2), 202-206, 2019 | 3401 | 2019 |
| Neoadjuvant PD-1 blockade in resectable lung cancer PM Forde, JE Chaft, KN Smith, V Anagnostou, TR Cottrell, MD Hellmann, ... New England Journal of Medicine 378 (21), 1976-1986, 2018 | 2064 | 2018 |
| Molecular determinants of response to anti–programmed cell death (PD)-1 and anti–programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell lung cancer profiled … H Rizvi, F Sanchez-Vega, K La, W Chatila, P Jonsson, D Halpenny, ... Journal of clinical oncology 36 (7), 633-641, 2018 | 1294 | 2018 |
| Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy J Naidoo, X Wang, KM Woo, T Iyriboz, D Halpenny, J Cunningham, ... Journal of Clinical Oncology 35 (7), 709-717, 2017 | 1124 | 2017 |
| Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer MD Hellmann, T Nathanson, H Rizvi, BC Creelan, F Sanchez-Vega, ... Cancer cell 33 (5), 843-852. e4, 2018 | 977 | 2018 |
| Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non–small-cell lung cancer KC Arbour, L Mezquita, N Long, H Rizvi, E Auclin, A Ni, G Martínez-Bernal, ... Journal of Clinical Oncology 36 (28), 2872-2878, 2018 | 934 | 2018 |
| Serpins promote cancer cell survival and vascular co-option in brain metastasis M Valiente, AC Obenauf, X Jin, Q Chen, XHF Zhang, DJ Lee, JE Chaft, ... Cell 156 (5), 1002-1016, 2014 | 872 | 2014 |
| Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer L Derosa, MD Hellmann, M Spaziano, D Halpenny, M Fidelle, H Rizvi, ... Annals of Oncology 29 (6), 1437-1444, 2018 | 801 | 2018 |
| Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study S Antonia, SB Goldberg, A Balmanoukian, JE Chaft, RE Sanborn, A Gupta, ... The lancet oncology 17 (3), 299-308, 2016 | 669 | 2016 |
| Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer JC Osorio, A Ni, JE Chaft, R Pollina, MK Kasler, D Stephens, C Rodriguez, ... Annals of Oncology 28 (3), 583-589, 2017 | 639 | 2017 |
| Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies EJ Jordan, HR Kim, ME Arcila, D Barron, D Chakravarty, JJ Gao, ... Cancer discovery 7 (6), 596-609, 2017 | 613 | 2017 |
| Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer H Yasuda, E Park, CH Yun, NJ Sng, AR Lucena-Araujo, WL Yeo, ... Science translational medicine 5 (216), 216ra177-216ra177, 2013 | 586 | 2013 |
| Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study MC Garassino, BC Cho, JH Kim, J Mazières, J Vansteenkiste, H Lena, ... The Lancet Oncology 19 (4), 521-536, 2018 | 570 | 2018 |
| Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint MD Hellmann, JE Chaft, WN William, V Rusch, KMW Pisters, N Kalhor, ... The lancet oncology 15 (1), e42-e50, 2014 | 566 | 2014 |
| Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas ME Arcila, JE Chaft, K Nafa, S Roy-Chowdhuri, C Lau, M Zaidinski, ... Clinical cancer research 18 (18), 4910-4918, 2012 | 527 | 2012 |
| EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics ME Arcila, K Nafa, JE Chaft, N Rekhtman, C Lau, BA Reva, MF Zakowski, ... Molecular cancer therapeutics 12 (2), 220-229, 2013 | 511 | 2013 |
| Perioperative pembrolizumab for early-stage non–small-cell lung cancer H Wakelee, M Liberman, T Kato, M Tsuboi, SH Lee, S Gao, KN Chen, ... New England Journal of Medicine 389 (6), 491-503, 2023 | 473 | 2023 |
| Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for … JE Chaft, GR Oxnard, CS Sima, MG Kris, VA Miller, GJ Riely Clinical cancer research 17 (19), 6298-6303, 2011 | 473 | 2011 |
| Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC) TR Cottrell, ED Thompson, PM Forde, JE Stein, AS Duffield, ... Annals of Oncology 29 (8), 1853-1860, 2018 | 436 | 2018 |
| Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1–selected advanced non–small-cell lung cancer (BIRCH) S Peters, S Gettinger, ML Johnson, PA Jänne, MC Garassino, D Christoph, ... Journal of Clinical Oncology 35 (24), 2781-2789, 2017 | 409 | 2017 |
